Evaluating muscle health in patients with blood cancers
The Prevalence and the Prognostic Value of Sarcopenia Among Patients With Haematological Cancer Diseases - A Prospective Observational Cohort Study.
This study is trying to see if having less muscle can affect how well people with blood cancers like leukemia and lymphoma respond to treatment and their long-term health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 216 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT05150561 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence and prognostic significance of sarcopenia in patients diagnosed with hematological cancers such as acute myeloid leukemia and lymphoma. It focuses on understanding how body composition at diagnosis may influence treatment outcomes and long-term prognosis. By evaluating muscle mass and strength, the study seeks to identify potential correlations between muscle health and disease progression. The findings could inform clinical practices regarding the management of patients undergoing treatment for these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with malignant lymphomas, acute leukemia, or multiple myeloma who are referred for treatment at the participating hospital.
Not a fit: Patients under 18, pregnant individuals, or those with disabilities that prevent muscle function testing will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that enhance patient outcomes by addressing muscle health in hematological cancer patients.
How similar studies have performed: While the specific focus on sarcopenia in hematological cancers may be novel, related studies have shown that muscle health can significantly impact treatment outcomes in cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Patients diagnosed with malignant lymphomas, acute leukaemia and multiple myeloma referred to treatment at the Department of Haematology, Rigshospitalet. Exclusion Criteria: * Age: \<18 * Pregnancy * Physical or mental disabilities precluding test of muscle function * Inability to read and understand Danish.
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Study coordinator: Jan Christensen, PhD
- Email: jan.christensen.02@regionh.dk
- Phone: 004535458511
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.